than 2 mg. Nobody was given more than 9 mg. In total, 350 mg of atropine was immediately necessary on the site of the attack, equivalent to 350 phials of 1 mg. In our simulation, the time for access and preparation of the antidote was about 10 minutes from the moment of the alert. The transfer and distribution time to the site was less than 15 minutes due to favourable road access, geographical factors and the short distance from the station to the storage facility.

**Conclusions** The pharmacist is responsible for immediate availability, accessibility and distribution of the antidotes to the site of emergency, and awareness of appropriate treatment.

No conflict of interest.

---

**Background** Electronic prescribing (EP) systems have been recognised as successful in reducing chemotherapy prescribing errors. However, electronic prescriptions are unlikely to prevent all errors, and new types of errors may emerge.

**Purpose** To assess prescribing error rates and identify new error types and their causes with the implementation of a electronic prescribing system for ambulatory cancer patients at a London Cancer Centre.

**Materials and Methods** A service evaluation was conducted in two parts, covering two different strategies for interception of prescribing errors – prospectively by pharmacists during a 2-week period, and retrospectively using data from the pharmacy EP telephone helpline service, over 41 weeks.

**Results** The overall rate of error-containing prescriptions was estimated to be 6%.

In the prospective part, 32 errors were identified from 571 electronic chemotherapy prescriptions. Most commonly committed errors were chemotherapy drug dose adjustments (13; 41%) and weight omissions (11; 34%).

In the retrospective analysis, 95 of 141 errors (67%) were ‘selection errors’, classified mainly as ‘work-arounds’ (26; 18%), ‘wrong commands’ (35; 25%), or ‘wrong fields’ (27; 19%). 65 errors (45%) were related to scheduling a chemotherapy or supportive drug or regimen.

Electronic system-related causes of prescribing errors were recognised in 4 of 32 cases (13%) in the prospective part, and in 59 of 141 cases (43%) in the retrospective part. It was estimated that with implementation of technical solutions and additional prescriber training, 58% of these errors could be prevented in the future.

**Conclusions** The estimated rate of chemotherapy prescribing errors was 6%. A number of different errors, specific for electronic prescribing, were identified, with a thorough explanation of how various errors may have occurred. Future larger scale studies are needed to confirm prescribing error rates, and to possibly identify other, previously unrecognised, types of chemotherapy prescribing errors.

No conflict of interest.